1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cardiac Fibrosis - Pipeline Review, H2 2014, Global Markets Direct

Cardiac Fibrosis - Pipeline Review, H2 2014, Global Markets Direct

  • September 2014
  • -
  • Global Markets Direct
  • -
  • 63 pages

Cardiac Fibrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Cardiac Fibrosis - Pipeline Review, H2 2014’, provides an overview of the Cardiac Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cardiac Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cardiac Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cardiac Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cardiac Fibrosis - Pipeline Review, H2 2014, Global Markets Direct
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cardiac Fibrosis Overview 6
Therapeutics Development 7
Pipeline Products for Cardiac Fibrosis - Overview 7
Pipeline Products for Cardiac Fibrosis - Comparative Analysis 8
Cardiac Fibrosis - Therapeutics under Development by Companies 9
Cardiac Fibrosis - Therapeutics under Investigation by Universities/Institutes 10
Cardiac Fibrosis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cardiac Fibrosis - Products under Development by Companies 13
Cardiac Fibrosis - Products under Investigation by Universities/Institutes 14
Cardiac Fibrosis - Companies Involved in Therapeutics Development 15
Daiichi Sankyo Company, Limited 15
BioLineRx, Ltd. 16
Galectin Therapeutics, Inc. 17
Digna Biotech, S.L. 18
Promedior, Inc. 19
miRagen Therapeutics, Inc. 20
Cardiac Fibrosis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
CARD-024 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
SP-20102 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
P-17 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
disitertide - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
CGEN-856 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
GM-CT-01 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
PRM-151 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
MGN-4220 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
GR-MD-02 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
PN1-Ab - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
TM-5441 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Cardiac Fibrosis - Recent Pipeline Updates 49
Cardiac Fibrosis - Dormant Projects 60
Cardiac Fibrosis - Product Development Milestones 61
Featured News and Press Releases 61
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables

Number of Products under Development for Cardiac Fibrosis, H2 2014 7
Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Cardiac Fibrosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 15
Cardiac Fibrosis - Pipeline by BioLineRx, Ltd., H2 2014 16
Cardiac Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 17
Cardiac Fibrosis - Pipeline by Digna Biotech, S.L., H2 2014 18
Cardiac Fibrosis - Pipeline by Promedior, Inc., H2 2014 19
Cardiac Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Cardiac Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 49
Cardiac Fibrosis - Dormant Projects, H2 2014 60

List of Figures

Number of Products under Development for Cardiac Fibrosis, H2 2014 7
Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Target, H2 2014 22
Number of Products by Stage and Top 10 Target, H2 2014 23
Number of Products by Top 10 Mechanism of Action, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 25
Number of Products by Top 10 Route of Administration, H2 2014 26
Number of Products by Stage and Top 10 Route of Administration, H2 2014 27
Number of Products by Top 10 Molecule Type, H2 2014 28
Number of Products by Stage and Top 10 Molecule Type, H2 2014 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.